General Oncology, Inc.
- Biotech or pharma, therapeutic R&D
General Oncology is a biopharmaceutical company developing GO-4, a phase 1 asset demonstrating a substantial signal of efficacy against BRCA-mutated pancreatic cancer, with a median PFS of at least 14.2 months in patients similar to those expected to be enrolled in the upcoming phase 2 potentially pivotal study (median not yet reached; range: 4.9–42.1 months). The company was founded by Arnold Glazier, M.D., who pioneered treating BRCA-mutated pancreatic cancer with DNA-crosslinking therapy supported by stem cell infusion, leading to the cure of his sister (now 13 years cancer-free) without any lasting side effects.
The company also has a deep pipeline of novel ultra-high potency small molecule compounds designed to treat metastatic and refractory cancers.
For more information about General Oncology, please visit www.generaloncology.com. Please no service provider meetings at this time.
Address
BrooklineMassachusetts
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}